Future Fields

futurefields.io →

-55%

est. 2Y upside i

HealthcareSeries A

We make unmakeable proteins with radical advanced biomanufacturing.

Rank

#881

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Future Fields presents a moderate upside opportunity driven by its innovative fruit fly biomanufacturing platform and strong competitive moat in a growing market.

Last updated: March 10, 2026

Bull (25%)+300%

Future Fields' proprietary EntoEngine™ platform achieves significant commercial traction in biopharma and cellular agriculture, successfully producing complex, difficult-to-express proteins at scale. Key partnerships and regulatory approvals accelerate market penetration, pushing revenue to over $100M by 2028 and justifying a $280M+ valuation (4x current) as a disruptive leader in sustainable biomanufacturing.

Base (50%)+75%

The company continues to grow steadily, securing additional contract manufacturing clients across its target industries. While facing competition from traditional and emerging biomanufacturing methods, Future Fields maintains its niche, reaching approximately $40M in revenue by 2028 and achieving a $122.5M valuation (1.75x current) at a Series C or acquisition.

Bear (25%)-80%

Scaling challenges, intense competition from well-funded incumbents, or slower-than-expected regulatory approvals limit growth and market adoption. Revenue stalls, leading to a down round or an exit at a valuation below current levels, resulting in a $14M valuation. Given the $22M in liquidation preferences, common stock holders would receive little to no return.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Investors hold $22M in liquidation preferences ahead of common shareholders on an estimated $70M valuation.

Dilution Risk

moderate

As a Series A company, Future Fields will likely undergo 1-2 more significant funding rounds (Series B, C) before a liquidity event, leading to further dilution.

Secondary Liquidity

none

There are currently no indications of active secondary markets or tender offers for Future Fields' shares.

Questions to Ask at the Interview

Strategic questions based on Future Fields's data — designed to show you've done your homework.

  • 1

    “How is Future Fields planning to navigate the complex regulatory landscape for its diverse applications in biopharma, food, and agriculture, especially given the novel nature of the EntoEngine™ platform?”

  • 2

    “With large incumbents like Thermo Fisher Scientific and Merck in the recombinant protein manufacturing space, what is Future Fields' strategy to convert their disruptive technology into significant market share and long-term client relationships?”

  • 3

    “Given the Series A funding and the estimated current valuation, what is the company's anticipated timeline and strategy for future funding rounds and eventual liquidity events for employees?”

Community

Valuation Sentiment

Our model estimates -55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.